PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial
The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective strategies.
